The use of PD-1 or PD-L1 inhibitors can block the PD-1/PD-L1 pathway, thereby enhancing the activity of T lymphocytes, enhancing the recognition and killing effect of tumor cell [69]. Here, PDCD1 is linked to neoplasm.